I've come to the same conclusion as MarsC. As for being cashflow positive, ACR have had ample time to inform shareholders how our testosterone generic is going. Dash Pharma would know how it's going after some 8-9 months, and if it wasn't working out for them they certainly would have told ACR by now. So whilst not expecting much, any good news will surprise. It's some 7-8 years since this path was taken and we are getting close to the Day of Truth.
Ann: Acrux's fifth generic dossier accepted by FDA for review, page-23
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.44M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32722 | 6.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.4¢ | 50000 | 1 |
View Market Depth
| Last trade - 10.46am 11/07/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable